Abstract
INTRODUCTION
An increased chance of developing Alzheimer’s disease (AD) or Parkinson’s disease later in life has been linked to infections with the influenza virus and other common viruses, according to an examination of about 450,000 electronic health records. One of the strongest correlations was found between viral encephalitis, an uncommon brain inflammation that can be brought on by a variety of viruses, and AD. In comparison to those who did not have encephalitis, those with encephalitis had a later-life risk of AD that was roughly 31 times higher [1, 2].
West Nile virus (WNV) is the main mosquito-borne disease in the continental United States. The most typical way for WNV to spread to humans is by a mosquito bite. The mosquito season, which begins in the summer and lasts until the fall, is when WNV cases develop. The majority of WNV carriers have no symptoms. One in five infected individuals have fever and other symptoms. One in 150 infected individuals develop encephalitis [3].
In a previous study, we were able to confirm the association of viral encephalitis with AD and suggest that WNV infection is a significant AD risk factor. A genome wide association study (GWAS) with UK Biobank data revealed that the gene RAR Related Orphan Receptor B (RORB) is significantly associated with viral encephalitis. [4]. RORB is an AD vulnerability factor [5] and an epilepsy gene [6]. Results in Finngen indicate that epilepsy increases risk of viral encephalitis, and thus AD, with hazards ratio 4.92 [7].
Some mutations and polymorphisms have been identified to increase the risk of acute infection-induced encephalitis. For instance, rare variants of the SCN1A and RANBP2 genes, thermolabile CPT2 variants, and HLA genotypes are some of the genetic factors that have been associated with encephalitis [8].
In the current study, we used data from PheWeb [9] to identify genes other than RORB that might be involved in both infectious encephalitis and AD. We did so because in our previous study of UK Biobank data, we had only 18 cases of viral encephalitis. We used UK Biobank data in the current study to examine gene expression and phenotypic expression.
Mammalian Target of Rapamycin, or mTOR, is a protein kinase that plays a crucial role in the regulation of cell growth, proliferation, and survival. It is involved in cellular processes, including protein synthesis, autophagy, and metabolism. Dysregulation of mTOR signaling has been implicated in the pathogenesis of several diseases, including neurodegenerative disorders and AD. The RPTOR gene (Regulatory-Associated Protein Of MTOR) is part of the mTOR pathway [10].
RPTOR is associated with body mass index (BMI) and obesity [11–13]. AD is associated with low BMI in old age [14]. Because of these associations and association with RPTOR snp rs12940622, which we studied here, we prioritized BMI as an outcome.

PheWeb GWAS results for 134 cases of encephalitis (A) and 114 cases of non-infectious encephalitis (B). RANBP3 L and RPTOR are significantly associated with encephalitis (A). Most encephalitis cases that have been diagnosed in the United States are infectious, caused by enteroviruses, arboviruses (including the West Nile Virus), and herpes simplex virus types 1 and 2. We have excluded RANBP3 L (B), associated with non-infectious encephalitis, from our analysis.
METHODS
PheWeb is a user-friendly, open-source web application for sharing, exploring, and visualizing GWAS results [9]. PheWeb includes findings from GWAS of 1,542 broad phenome wide association studies (PheWAS) codes collected from electronic health records for over 51.8 million imputed variations in 51,583 individuals of European ancestry from the Michigan Genomics Initiative, a biobank of patients at Michigan Medicine. The PheWAS R package (https://github.com/PheWAS/PheWAS) is used to extract diagnosis codes from patient electronic health records and generate phenotypes. The TOPMed reference panel is used to impute genetic data in Michigan Genomics Initiative participants to provide association testing at high-quality genetic variants for each phenotype. Pheome-wide association analysis of individual genetic variants and interactive study of individual GWAS are made possible via the PheWeb interface. The gene RPTOR emerged in the GWAS (see results below).
To examine RPTOR in relation to AD and BMI we used UK Biobank data. The UK Biobank (UKBB) is a large prospective observational study comprising approximately 500,000 men and women (
Data processing was performed on Minerva, a Linux mainframe with Centos 7.6, at the Icahn School of Medicine at Mount Sinai. We used PLINK, a whole-genome association analysis toolset, to analyze the UKB chromosome files [15] and the UK Biobank Data Parser (ukbb parser), a python-based package that allows easy interfacing with the large UK Biobank dataset [16]. PheWeb uses LocusZoom for the Manhattan and q-q plots and calculation of lambda, the genetic control inflation factor [17].
RESULTS
Figure 1A displays PheWeb GWAS results for 134 cases of encephalitis and 114 cases of non-infectious encephalitis (Fig. 1B). RANBP3 L and RPTOR are significantly associated with encephalitis, but RANBP3 L is associated with non-infectious encephalitis. Most encephalitis cases that have been diagnosed in the United States are infectious, caused by enteroviruses, arboviruses (including the WNV), and herpes simplex virus types 1 and 2, which are spread from infected animals to humans through the bite of an infected tick, mosquito, or other bloodsucking parasite [18]. We have excluded RANBP3 L from our analysis to eliminate cases of non-infectious encephalitis.
Figure 2A shows the QQ plot of p values from encephalitis data (Fig. 1A). Note that the leftmost p-values observed follow a uniform distribution (lower segment of line) but those that are in linkage disequilibrium with causal polymorphisms produce significant p-values (right segment of line). The genomic control inflation factor lambda, calculation based on the 50th percentile (median), is 0.205. Values up to 1.1 are generally considered acceptable for GWAS and suggest no systematic biases. Figure 2B is the QQ plot of p values from non-infectious encephalitis data (Fig. 1B, lambda 0.188).

A) QQ plot of p values from encephalitis data (Fig. 1A). Note that the leftmost p-values observed follow a uniform distribution (lower segment of line) but those that are in linkage disequilibrium with causal polymorphisms produce significant p-values (right segment of line). The genomic control inflation factor lambda, calculation based on the 50th percentile (median), is 0.205. Values up to 1.1 are generally considered acceptable for GWAS and suggest no systematic biases. B) QQ plot of p values from non-infectious encephalitis data (Fig. 1B, lambda 0.188).
Table 1 shows RPTOR snp rs12940622 genotype versus AD in 187,297 subjects age < 55. Note that subjects homozygous for the major allele G had increased prevalence of AD, while subjects heterozygous or homozygous for the minor allele A had decreased prevalence of AD (
RPTOR genotype versus AD in 187,297 subjects age < 55. Note that subjects homozygous for the major allele G had increased prevalence of AD, while subjects heterozygous or homozygous for the minor allele A had decreased prevalence of AD (p = 0.05, two tail Fisher exact test)
Table 2 shows logistic regression with 95% confidence intervals, AD in subjects < age years dependent variable, sex, age, and RPTOR genotype independent variables. Increasing age was significantly associated with more AD (odds ratio [O.R.] 1.240). Subjects heterozygous or homozygous for the RPTOR minor allele A had decreased risk of AD (O.R. 0.517).
Logistic regression with 95% confidence intervals, AD in subjects < 55 years dependent variable, sex, age, and RPTOR genotype independent variables, L.B., lower bound; O.R., odds ratio; U.B., upper bound. Increasing age was significantly associated with more AD (O.R. 1.240). Subjects heterozygous or homozygous for the RPTOR minor allele A had decreased risk of AD (O.R. 0.517)
RPTOR genotypes had a significant effect on BMI. 153,249 subjects homozygous for major allele G had higher BMI 27.4702±4.81742 (mean±SD). 330,564 subjects heterozygous or homozygous for the minor allele A had lower BMI 27.3953±4.77236. This difference was significant (
Table 3 shows logistic regression with 95% confidence intervals, AD in subjects all ages dependent variable, sex, age, and BMI independent variables. Reduced BMI was significantly associated with more AD (O.R. 0.982). Increasing age was significantly associated with more AD (O.R. 1.213). Male sex was significantly associated with a higher odds ratio of AD (O.R. 1.198).
Logistic regression with 95% confidence intervals, AD in subjects all ages dependent variable, sex, age, and BMI independent variables. Reduced BMI was significantly associated with more AD (O.R. 0.982). Increasing age was significantly associated with more AD (O.R. 1.213). Male sex was significantly associated with more AD (O.R. 1.198)
DISCUSSION
The RPTOR gene is associated with the mTOR pathway [10]. mTOR is a protein kinase that plays a crucial role in the regulation of cell growth, proliferation, and survival. It is involved in cellular processes, including protein synthesis, autophagy, and metabolism. Dysregulation of mTOR signaling has been implicated in the pathogenesis of several diseases, including neurodegenerative disorders and AD.
AD is a neurodegenerative disorder that is characterized by the accumulation of amyloid-β and tau proteins in the brain [19]. mTOR is a central regulator of protein synthesis in neurons, and its signaling has been linked to neurodegenerative diseases such as AD [20]. In AD, the inhibition of mTOR by rapamycin ameliorates the synthesis of amyloid-β and tau protein and improves learning and memory abilities [20]. Autophagy is a cellular recycling process that is required to prevent the buildup of misfolded protein aggregates that contribute to the development of neurodegenerative diseases [21]. In the central nervous system, autophagy and its regulation by mTOR are critical for maintaining neuronal functions such as synaptic remodeling and plasticity associated with long-term memory formation [20]. Synaptic plasticity is the ability of synapses to strengthen or weaken over time in response to changes in their activity, and it is essential for learning and memory [20]. Neuronal function is the ability of neurons to communicate with each other and is critical for the proper functioning of the nervous system [20]. Therefore, mTOR-regulated autophagy plays an important role in the synaptic plasticity-related proteins alterations and the decline of cognitive function in AD [20].
The mTOR pathway can affect encephalitis susceptibility. Viral infections can activate, reduce, or even suppress the mTOR pathway. In addition, viruses have evolved various mechanisms to attack and co-opt the mTOR pathway to make the host cell a hospitable environment for replication [22]. We are unable to determine whether the specific variant, the RPTOR snp rs12940622, is associated with encephalitis. However, the GWAS data we present indicate that RPTOR is associated with encephalitis.
The RPTOR gene snp rs12940622 is related to BMI [11–13]. BMI is a measure of body mass based on an individual’s height and weight. It is widely used as a screening tool to categorize individuals into different weight categories, such as underweight, normal weight, overweight, and obesity. Increase in body weight often results from obesity (increased adipose tissue mass) but also from, for example, muscle mass. We were able to confirm the RPTOR-BMI relationship in UKBB data above, although the effect size was small [23]. There were no other hits in the data we examined.
While there is evidence that RPTOR can influence susceptibility to obesity, multiple genes are likely involved, and the interplay between genetic and environmental factors is complex. Numerous genetic variants have been associated with obesity-related traits, but the specific contribution of each gene and how they interact is still an area of active research [24].
Studies of the association between BMI and AD have yielded mixed findings [25]. There may be a link between being underweight or having low BMI and an increased risk of developing AD [26]. Malnutrition or other factors related to low BMI may influence cognitive function negatively. Obesity is a well-known risk factor for various health conditions, including cardiovascular diseases and type 2 diabetes. A possible link may exist between obesity and an increased risk of developing AD [25]. Indeed, both low and high BMI may be associated with an increased risk of AD, indicating a potential U-shaped relationship, the obesity paradox: obesity in midlife, low BMI in old age [14]. But any relationship between BMI and AD is complex, and additional factors such as age, genetics, and overall health contribute to the risk.
Infectious encephalitis disrupts the blood-brain barrier [27, 28] and derangements of the blood-brain barrier are an important part of AD [29]; however, our study is limited by inability to directly evaluate effects on the blood-brain barrier. Confirmatory studies with mRNA expression of the RPTOR snp rs12940622 variant or tissue/blood level of RPTOR protein expression would support findings presented here. A Mendelian randomization study to examine the causal relationship between encephalitis and AD would be important in future studies.
Most studies report that AD is more common in women; however, in the UKBB, AD is more common in men, which has been reported previously. In another study of UK Biobank data, men had a higher risk of all-cause, young-onset and late-onset dementias than women [30].
In conclusion, mTOR and RPTOR may represent potential therapeutic targets for AD, due to their involvement in various cellular processes implicated in AD. Modulating RPTOR and mTOR activity may have the potential to regulate protein synthesis, enhance autophagy, and improve neuronal function in people with AD. The role of RPTOR and mTOR in AD is complex, and both excessive and insufficient mTOR activity may have negative effects. Balancing mTOR activity to achieve therapeutic benefits without causing harmful side effects will be a challenge.
AUTHOR CONTRIBUTIONS
Steven Lehrer (Conceptualization; Data curation; Writing - Original Draft); Peter H. Rheinstein, MD, JD, MS (Conceptualization).
